%0 Journal Article
%T Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors
%A Angela Omilian
%A Antonios Papanicolau-Sengos
%A Blake Burgher
%A Carl Morrison
%A Felicia L. Lenzo
%A Fiona C.L. Hyland
%A Igor Puzanov
%A Jeffrey M. Conroy
%A Ji He
%A Jonathan Andreas
%A Lorenzo Galluzzi
%A Marc S. Ernstoff
%A Mark Gardner
%A Mary Nesline
%A Moachun Qin
%A Sarabjot Pabla
%A Sean T. Glenn
%A Vincent Giamo
%A Wiam Bshara
%J The Journal of Molecular Diagnostics
%D 2018
%R 10.1016/j.jmoldx.2017.10.001
%X We have developed a next-generation sequencing assay to quantify biomarkers of the
host immune response in formalin-fixed, paraffin-embedded (FFPE) tumor specimens.
This assay aims to provide clinicians with a comprehensive characterization of the
immunologic tumor microenvironment as a guide for therapeutic decisions on patients
with solid tumors. The assay relies on RNA-sequencing (seq) to semiquantitatively
measure the levels of 43 transcripts related to anticancer immune responses and 11
transcripts that reflect the relative abundance of tumor-infiltrating lymphocytes,
as well as on DNA-seq to estimate mutational burden.
%U https://jmd.amjpathol.org/article/S1525-1578(17)30363-X/fulltext